Objective: Between September 1991 and July 1996, 60 patients (mean age 29.89 9 years; range 5 -57) underwent aortic root replacement with pulmonary autograft, a viable biologic and nondegenerating substitute. The pulmonary root was replaced with cryopreserved homografts from cardiac transplant recipients. The aim of this study was to evaluate differences in early valve function of viable and cryopreserved allografts. Methods: All patients had Doppler echocardiographic examinations preoperatively, at discharge from hospital and 54 patients at 1 year follow-up. We measured aortic and pulmonary peak flow velocities with continuous and pulsed-wave Doppler, and graded aortic and pulmonary insufficiency (AI, PI) with color Doppler flow (grade 0-IV). Intraoperatively, the diameters of the pulmonary root and the pulmonary homograft were measured with standard valve probes and matched to body surface area. Results: Pulmonary peak flow velocity (PV max ) increased significantly from preoperative 0.87 90.11 m/s to 1.309 0.34 m/s postoperatively (P B0.001). The implanted homografts (mean 25.992.4 mm) were larger than their native pulmonary diameter (mean 23.391.8 mm) in all patients. Homograft size matched for body surface area (BSA) did not correlate with increased PV max . There was a significant increase of PV max at follow-up (FU) since discharge, also (1.83 90.53 m/s; PB0.001). Pulsed-wave Doppler demonstrates that increase of PV max is located directly at the homograft leaflets and not at the anastomoses. Aortic peak flow velocities (AV max ) were normal postoperatively and at FU (post= 1.3590.35 m/s; FU= 1.179 0.27 m/s). There was no significant change in AI or PI since discharge (AI FU= 0.89 0.4; PI FU= 0.79 0.5). Eight patients with fever and symptoms diagnosed as post-pericardiotomy syndrome had significantly higher PV max at FU (PV max = 2.41 90.40 m/s; P B 0.02). Conclusions: The Ross procedure leads to normal AV max but significant increase of PV max even in oversized cryopreserved homografts immediately after surgery. Further increase of PV max without changes in AV max in the first year demonstrates that changes in flow velocities are valve related and not due to increase in cardiac output. Further investigations will be necessary to determine whether this observation is due to valve rejection or early leaflet degeneration and treatment with immunosuppressive therapy is warranted. © 1997 Elsevier Science B.V.
Introduction
Pulmonary autograft is used in an increasing number of patients for aortic valve replacement because it is the only technique for implantation of a vital and nondegenerating valve substitute with hemodynamic performance similar to that of native aortic valves [1] [2] [3] . Freedom from thromboembolic events, evidence of growth in children and long-term results with a free-dom from valve-related complications of 70% at 20 years make the pulmonary autograft, especially in young patients, one of the best solutions for aortic valve replacement [2, 4, 5] .
Because of the reported viability of cryopreserved allografts, mostly cryopreserved pulmonary homografts from cardiac transplant recipients are chosen for reconstruction of the right ventricular outflow tract [6, 7] . Cryopreservation does not alter antigenicity of aortic allografts and the immunologic response may influence early and late valve function more than previously thought [8] [9] [10] .
The aim of our study was to compare early valve function of the viable pulmonary autograft and the cryopreserved homograft in patients after the Ross procedure.
Patients and methods
Since 1991, 60 patients with a mean age of 29.89 9 years (range 5-57 years) underwent pulmonary autograft valve replacement with their native pulmonary valve. Fourteen patients were younger than 18 years; there were 50 male and 10 female patients. In the first two patients, we used the subcoronary implantation technique, but all remaining 58 patients underwent aortic root replacement with direct implantation of the coronary arteries. All patients received cryopreserved pulmonary homografts from cardiac transplant recipients, mostly from our own homograft bank, for reconstruction of their right ventricular outflow tract. Only four homografts came from other institutions. The pulmonary valves were taken from donors younger than 55 years, prepared within 24 h and sterilized in a mixed antibiotic solution (vancomycin, cefoxitin, metronidazol, polymyxin B) for 24 h. They were then incubated in dimethyl sulfoxide (DMSO) as antioxidantium in the vapor phase of a liquid nitrogen container at − 174°C. No blood group or HLA matching was done. We use as an operative technique three running sutures for proximal and one running suture for the distal homograft anastomosis.
The mean aortic cross-clamp time was 118 9 23 min, mean extracorporal circulation time 165.49 35 min. Additional surgery was performed in four patients (mitral valve reconstruction in two, VSD closure and abnormal pulmonary vein inflow in two other patients). In 70% of the patients (n =42), the pathology was isolated aortic regurgitation.
Preoperatively, the mean New York Heart Association (NYHA) class was 2.8 90. 4 . In asymptomatic patients, we try to operate before irreversible ventricular dilatation or reduced ventricular function will occur.
Transthoracic echocardiography was performed preoperatively for evaluation for valve repair (n = 60), at discharge from hospital (n = 59) and at 1 year followup (n= 54). Intraoperatively, the operative results were proven with transesophageal echocardiography. We used Hewlett Packard Sonos 1500 and 2500 machines with 2.2/2.5 MHz transthoracic and 5 MHz transesophageal probes. During each echocardiographic examination, aortic and pulmonary insufficiency (AI, PI) were graded with color Doppler flow from the width and length of the regurgitant jet into the left or right ventricular outflow tract and ventricles (grade 0-IV).
The maximum aortic and pulmonary flow velocities (AV max , PV max ) were measured with continuous wave Doppler (normal: AV max = 1.0-1.8 m/s; PV max =0.6-0.9 m/s). Pulsed-wave Doppler was used for localization of the gradient drop at the right ventricular outflow tract and the pulmonary homograft to determine the origin of increased flow velocity whether it came from the anastomosis or the homograft leaflets. All echocardiographic measurements were averaged from three cardiac cycles. Intraoperatively, the diameters of pulmonary autografts and homografts were measured with standard valve probes and matched to body surface area.
Data are presented as mean 9S.D. Changes in echocardiographic measurements from pre-to postoperatively and at follow-up were analyzed by the paired t-test. P-values of less than 0.05 were considered significant.
Results
One patient died because of sudden cardiac death on the 5th postoperative day (perioperative mortality= 1.7%). At the beginning of our series, two patients were reoperated because of residual aortic regurgitation within the first year. In both patients, leaflet perforation of the pulmonary autograft could be reconstructed with a glutaraldehyde-fixated pericardial patch. One patient established moderate pulmonary regurgitation with homograft endocarditis 5 months postoperatively and was treated medically. He was excluded from pulmonary flow velocity measurements at follow-up. All patients were in NYHA class I, except for one patient with moderate AI at follow-up and the patient after homograft endocarditis, who were in NYHA class II.
Aortic regurgitation decreased significantly from pre- Intraoperatively, the pulmonary diameters were measured (mean 23.39 1.8 mm; range 17 -29 mm). All native pulmonary roots were smaller than the implanted pulmonary homografts (mean 25.9 92.4 mm; range 21-31 mm). There was no correlation between homograft size matched for body surface area and increased pulmonary flow velocities (see Fig. 1 ).
Moving the sample volume of the Doppler beam from the right ventricular outflow tract through the homograft leaflets to the pulmonary artery, pulsedwave Doppler showed that the increase of pulmonary flow velocity is located at the homograft leaflets and not at the anastomosis in all patients.
Eight patients developed fever and symptoms of chest and/or pleuritic pain, malaise and weakness within the first postoperative month, but none had signs of infection (negative blood cultures, no homograft regurgitation or vegetations). These symptoms were diagnosed as post-pericardiotomy syndrome. Interestingly, those patients had significantly higher pulmonary flow velocities at follow-up (mean PV max , 2.419 0.40 m/s; PG, 23.2+ 2.3 mmHg; range, 1.97-3.01; PB 0.02; n=8) (see Fig. 2 ). Fig. 2 . Flow velocities, pressure drops and regurgitation fraction preoperatively, at discharge and at follow-up (AV max , peak aortic flow velocity (m/s); AG, aortic peak gradient; PV max , pulmonary peak flow velocity; PG, peak gradient (mmHg); PI, pulmonary incompetence).
Conclusions
Patients after aortic valve replacement with pulmonary autograft received their living pulmonary valve as a nondegenerating substitute with a reported durability of more than 90% freedom from valve-related complications at 10 years and 70% after 20 years [5, 11, 12] . This type of valve replacement is the only substitute with hemodynamic performances that are similar to native aortic valves [3, 15] and makes the Ross procedure the operation of choice in young patients with aortic valve disease [2, 3, 12] . In our series, all patients had normal aortic flow velocities at discharge and at follow-up, with a very low incidence of residual regurgitation. Only two patients during our learning curve with this complex operation had to be reoperated in the first year. No reoperation occurred in the last 5 years.
The need for reconstruction of the right ventricular outflow tract makes this operation for a double valve replacement with cross-clamp times of about 2 h [16] . However, with the routine use of retrograde blood cardioplegia, we demonstrate that operative mortality of 1.7% is acceptable for such perfect hemodynamic results in mostly active and young patients. For reconstruction of the right ventricular outflow tract, mostly cryopreserved homografts are used because of its reported viability. However, longer durability is discussed controversially [12, 15] . At long term follow-up, homograft stenosis due to leaflet degeneration is the main cause of reoperation [7] and oversizing could be one option for longer valve survival.
Echocardiography is today the gold standard in the follow-up program in patients after cardiac valve replacement [13, 14, 17] . Especially with modern Doppler technologies, changes in blood flow velocities due to valvular dysfunction after aortic valve replacement can be observed very early before symptoms occur, and timing of optimal treatment is possible. In patients after the autograft procedure, most interest is directed to- ward the aortic position, but in the long-term followup, the pulmonary homograft might be the major cause of reoperations [7] .
We observed a significant increase in pulmonary flow velocities from the preoperative to the postoperative stage, and from discharge to 1 year follow-up. There was no change in aortic flow velocities in the same time, demonstrating that there was no change in cardiac output. Flow velocities at semilunar valves are dependent on the blood volume and orifice area. Increase of cardiac output accelerates both aortic and pulmonary flow velocities. The observation of isolated increase of pulmonary flow velocity demonstrates that the pulmonary homograft valve area is smaller than the native pulmonary valve of the patient even in these oversized homografts. We compared intraoperatively measured homograft size matched to body surface area with measurements of the patients native pulmonary valve. There was no correlation with increased pulmonary flow velocities. Pulsed-wave Doppler demonstrates that the gradient is located directly at the homograft leaflets and not at the anastomosis. We conclude that increased flow velocities are valve related and stiffness of the homograft leaflets or the homograft wall, even in cryopreserved homografts, decreases valve opening. Eight patients with fever and symptoms diagnosed as postpericardiotomy syndrome had significantly higher flow velocities at their homografts after 1 year, but none of these patients had signs of infection. The one excluded patient, after homograft endocarditis, established moderate homograft insufficiency with normal pulmonary flow velocity. We conclude that some immunologic response after allograft implantation leads to infiltration or edema of the homograft leaflets and may affect valvular function. We know from other studies that cryopreservation does not alter antigenic expression of aortic allografts. In addition, with in situ hybridization, living donor fibroblasts could be isolated years after implantation of cryopreserved allografts [9] . Shortcourse cyclosporin A immunosuppressive therapy lead to better allograft valve survival in rats [19] . Also, heterografts in the pulmonary position showed impaired long-term results both in animals and humans in comparison to aortic valve replacement. Other groups had published unexplained fever in about 25% of the patients after implantation of cryopreserved allografts [18] .
Most of our patients are in NYHA class I and only echocardiography shows impaired homograft function. Mid-term and long-term follow-up will show if early increase of pulmonary flow velocities is correlated with allograft long-term durability. Patients with any symptoms of immunologic response should be treated very carefully and short-course immunosuppressive therapy should be discussed to increase homograft survival in the pulmonary position [10, 18, 19] .
